Intravitreal Tissue Plasminogen Activator in Diabetic Vitreous Hemorrhage



Reza NM¹ ; Hosein AM¹ ; Hesamsadat H¹ ; Amir EM¹ ; Narges H² ; Amin N¹ Show Affiliations
Source: International Journal of Pharmaceutical Research Published:2019

Abstract

Background and Purpose: Vitreous hemorrhage is one of the most common complications of diabetic retinopathy that causes significant visual impairment. So, the aim of this research was evaluation of the effect of intravitreal tissue plasminogen activator (tPA) on diabetic vitreous hemorrhage. Material and Methods: This is a Double blinded randomized clinical trial on 15 patients with diabetic vitreous hemorrhage received single dose of 80µ in 0.1 ml tPA intravitrealy and 15 patients received 1.25 mg intravitreal Bevacizumab (IVB). Visual acuity and vitreous hemorrhage grading before and after intervention were evaluated as main outcome. Results: 30 patients completed our study (15 patients in each group). Primary characteristics of two group had no differences significantly. Visual acuity before intervention had no significant difference between groups. After intervention visual acuity was significantly better in IVB group compared to tPA group (P=0.027). There was no significant difference between groups in term of vitreous hemorrhage grading before and after intervention. Visual acuity and grading of vitreous hemorrhage improved after intervention compared to the baseline in both groups. Conclusion: TPA is statistically effective in resolution of diabetic vitreous hemorrhage however, its effect is less than bevacizumab and its clinical benefit comparing to observation may need more evaluation. © 2019, Advanced Scientific Research. All rights reserved.